Benzinga · Aug 14, 2026
B of A Securities Maintains Neutral on Erasca, Raises Price Target to $20
B of A Securities analyst Alec Stranahan maintains Erasca (NASDAQ:ERAS) with a Neutral and raises the price target from $18 to $20.
ER
NASDAQ · ERAS
Erasca, Inc.
Healthcare · Biotechnology
$17.63
Up+$0.55 (+3.22%)
Updated Aug 22, 2026, 11:53 AM
SID Score
6.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 958.95M
- P/E ratio
- -7.47
- Dividend yield
- 0.00%
- 52-week range
- $1.33 – $24.28
- Volume
- 2.45M
- Avg. volume
- 1.84M
Price performance
ERAS price history
1M range · 21 trading sessions · Daily adjusted prices
ERAS closed at $17.63 after 21 trading sessions, down 7.74% for the selected period.
- Last close
- $17.63
- Period change
- -7.74%
- Period low
- $17.08
- Period high
- $19.11
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $17.28 | $17.835 | $17.21 | $17.63 | 2.45M |
| Aug 20, 2026 | $17.59 | $17.77 | $16.92 | $17.08 | 2.67M |
| Aug 19, 2026 | $18.77 | $18.77 | $17.705 | $18.07 | 3.31M |
| Aug 18, 2026 | $18.19 | $18.72 | $17.85 | $18.10 | 1.92M |
| Aug 17, 2026 | $18.38 | $18.72 | $18.01 | $18.28 | 2.22M |
| Aug 14, 2026 | $17.50 | $18.465 | $17.30 | $18.38 | 2.47M |
| Aug 13, 2026 | $18.96 | $18.96 | $17.78 | $17.86 | 2.6M |
| Aug 12, 2026 | $18.43 | $19.22 | $18.27 | $18.58 | 3.65M |
| Aug 11, 2026 | $18.03 | $18.57 | $17.48 | $18.31 | 3.43M |
| Aug 10, 2026 | $18.15 | $18.586 | $17.845 | $18.12 | 3.9M |
| Aug 7, 2026 | $18.61 | $18.7969 | $17.83 | $18.41 | 2.1M |
| Aug 6, 2026 | $18.33 | $18.98 | $18.08 | $18.27 | 2.43M |
| Aug 5, 2026 | $18.62 | $19.00 | $18.14 | $18.62 | 3.1M |
| Aug 4, 2026 | $18.19 | $18.865 | $17.91 | $18.38 | 4.76M |
| Aug 3, 2026 | $17.76 | $18.00 | $17.08 | $17.84 | 2.75M |
| Jul 31, 2026 | $18.725 | $18.92 | $17.77 | $18.15 | 2.7M |
| Jul 30, 2026 | $18.19 | $18.75 | $17.57 | $18.68 | 3.7M |
| Jul 29, 2026 | $18.00 | $18.45 | $17.13 | $17.72 | 4.2M |
| Jul 28, 2026 | $18.70 | $18.715 | $17.71 | $18.16 | 3.82M |
| Jul 27, 2026 | $19.03 | $19.96 | $18.803 | $18.87 | 3.53M |
| Jul 24, 2026 | $19.39 | $19.815 | $19.05 | $19.11 | 3.18M |
Latest ERAS news
The latest Smart Investors Daily articles mentioning ERAS.
Stock researchCompany · Overview
ERAS research
Overview
Company profile and research snapshot.
Company profile
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $5.50
- Implied upside
- —
- Analysts
- 16
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 14, 2026 | B of A Securities | Neutral | — |
| Aug 13, 2026 | Guggenheim | Buy | — |
| Aug 12, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 20, 2026 | Morgan Stanley | Equal-Weight | — |
| Jul 14, 2026 | B of A Securities | Neutral | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 13, 2026
Guggenheim Maintains Buy on Erasca, Raises Price Target to $21
Guggenheim analyst Paul Jeng maintains Erasca (NASDAQ:ERAS) with a Buy and raises the price target from $20 to $21.
Benzinga · Aug 12, 2026
HC Wainwright & Co. Maintains Buy on Erasca, Raises Price Target to $22
HC Wainwright & Co. analyst Andres Y. Maldonado maintains Erasca (NASDAQ:ERAS) with a Buy and raises the price target from $18 to $22.
Benzinga · Aug 11, 2026
Erasca Q2 EPS $(0.14) Misses $(0.11) Estimate
Erasca (NASDAQ:ERAS) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.11) by 27.27 percent. This is a 16.67 percent decrease over losses of $(0.12) per share from the
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
